Novartis Settlement Encompasses Whistleblower Claims Of Kickbacks For Diovan Prescribing

The company agrees to pay $422.5 million to resolve civil and criminal claims related to off-label use and kickbacks, including allegations that it paid doctors' speaking and consulting fees based upon the volume of prescriptions they wrote for its hypertension drugs.